|Title:||Benzimidazole compound crystal|
|Abstract:|| A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl],sulfinyl]- -1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.|
|Inventor(s):|| Fujishima; Akira (Sanda, JP), Aoki; Isao (Kawanishi, JP), Kamiyama; Keiji (Ibaraki, JP) |
|Assignee:|| Takeda Pharmaceutical Company Limited (Osaka, JP) |
|Filing Date:||Jan 07, 2008|
|Claims:||1. A method for manufacturing a preparation for oral administration, which comprises: formulating a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-- 1H-benzimidazole or a salt thereof and a pharmaceutically acceptable carrier into a first composition; and subsequently forming the preparation for oral administration. |
2. The method according to claim 1 wherein the X-ray powder diffraction analysis pattern of the crystal has characteristic peaks at the interplanar spacings (d) of 11.68, 6.77, 5.84, 5.73, 4.43, 4.09, 3.94, 3.89, 3.69, 3.41, and 3.11 Angstrom.